How big is the Mexico Oral Anti-Diabetic Drug Market?

June 2023: The FDA has approved the drugs Jardiance and Synjardy to be taken by children ages 10 and older who have type 2 diabetes.
March 2022: Eli Lilly and Boehringer Ingelheim gained approval, for heart failure treatment from the EU for sodium-glucose co-transporter-2-inhibitor (SGLT2-I), Jardiance (empagliflozin).

The Mexico Oral Anti-Diabetic Drug Market size is expected to reach USD 1.5 billion in 2024 and grow at a CAGR of greater than 3% to reach USD 1.8 billion by 2028. Read More

What is the current Mexico Oral Anti-Diabetic Drug Market size?

In 2024, the Mexico Oral Anti-Diabetic Drug Market size is expected to reach USD 1.5 billion. Read More

Who are the key players in Mexico Oral Anti-Diabetic Drug Market?

Astrazeneca, Astellas, Janssen, Eli Lilly and Sanofi are the major companies operating in the Mexico Oral Anti-Diabetic Drug Market. Read More

What years does this Mexico Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?

In 2023, the Mexico Oral Anti-Diabetic Drug Market size was estimated at USD 1.46 billion. The report covers the Mexico Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Mexico Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Mexico Oral Anti-Diabetic DrugCompanies

This report lists the top Mexico Oral Anti-Diabetic Drug companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Mexico Oral Anti-Diabetic Drug industry.